Medications · Sleep & recovery

Compounded Gabapentin

Gabapentin in liquid or alternative excipient preparations.

Start a prescription All medications →
Compounded Gabapentin molecular structure (Anticonvulsant / GABA analog)

Why this needs to be personal

Why Personalized Compounded Gabapentin

Neurontin's labeled dose schedule (300 mg day one, 600 mg day two, 900 mg day three, titrate to 1800, 3600 mg/day in three divided doses) was calibrated for an average adult with adequate kidney function and no specific sensitivity to the dye, sweetener, or flavoring in the commercial 250 mg/5 mL oral solution. That schedule does not account for a six-year-old who needs precise mg/kg dosing in a volume a child will actually swallow, an older adult with a creatinine clearance of 35 where the label demands a dose cut but the commercial strengths skip past the step you want, a patient with a documented reaction to FD&C yellow or to sorbitol in the brand solution, or a clinician trying to treat a small patch of post-surgical neuropathic pain on the foot where systemic gabapentin's sedation and gait risk are not worth it.

Compounding closes those gaps one at a time. A 50 mg/mL dye-free, sucrose-free oral suspension lets a pediatric prescriber dose by weight without a sweetener the child reacts to. A 50 mg or 200 mg custom capsule gives the older adult with renal impairment a titration step the commercial 100/300/400 mg strengths do not provide. A 6% or 10% topical gel keeps the molecule on the skin over the painful area instead of putting a sedating dose through the whole central nervous system, a route the manufacturer does not make. In every oral case the molecule is the same gabapentin the FDA reviewed in 1993; what changes is the strength, the excipient profile, and the route, fitted to one patient on one prescription.

This is what pharmacy looked like before mass manufacturing. A doctor wrote the prescription for a named patient, and a pharmacist prepared it for that patient. Modern 503A oversight, state licensure, batch documentation, pharmacist review of concomitant CNS depressants, keeps the older arrangement honest.

In brief

Compounded Gabapentin Explained

Gabapentin is a long-used prescription medicine for nerve pain and certain kinds of seizures. The brand-name versions are Neurontin (approved in 1993), Gralise (a once-daily form for shingles-related nerve pain), and Horizant (a slow-release form for restless legs syndrome). Despite its name, gabapentin does not act on GABA receptors, it works by quieting overactive nerves through a different protein on calcium channels 1.

RonanRx compounds gabapentin only when a prescriber documents that the manufactured product cannot meet a patient-specific need. Common reasons include children or adults with swallowing difficulty who need a liquid at a strength not commercially available, patients with a documented sensitivity to dye or another excipient in the brand, or clinicians prescribing a topical cream or gel for a small area of localized nerve pain, a use that is off-label and not commercially manufactured 293031. Compounded preparations are not FDA-approved and are not substitutes for the manufactured products 33.

At a glance

Quick Facts About Compounded Gabapentin

Category
Anticonvulsant / gabapentinoid, α2δ-1 ligand of voltage-gated calcium channels (not a GABA receptor agonist despite the name)
Active ingredient
Gabapentin, a γ-aminobutyric acid (GABA) structural analog that binds the α2δ-1 auxiliary subunit of voltage-gated calcium channels in the central nervous system
FDA-approved branded forms
Neurontin (immediate-release capsule, tablet, oral solution; approved 1993), Gralise (gastric-retentive once-daily tablet for postherpetic neuralgia; approved 2011), and Horizant (gabapentin enacarbil extended-release prodrug for restless legs syndrome and postherpetic neuralgia; approved 2011)
Route
Oral (capsule, tablet, solution) for manufactured products; compounded preparations include patient-specific oral suspensions, custom-strength capsules, and topical creams/gels for off-label localized pain
Evidence posture
FDA-approved indications (postherpetic neuralgia, adjunctive partial seizures, RLS for the enacarbil prodrug) supported by pivotal randomized trials; large additional well-studied evidence base for off-label diabetic peripheral neuropathy, fibromyalgia, hot flashes, and alcohol use disorder
FDA-approval status
Manufactured Neurontin, Gralise, and Horizant are FDA-approved. Compounded gabapentin preparations are not FDA-approved.
Compounded under
503A, patient-specific prescription only, where the manufactured FDA-approved product is not clinically appropriate (excipient sensitivity, dose individualization outside commercially available strengths, dysphagia requiring liquid not in stock, or topical use not commercially available)
Important compounding caution
Neurontin oral solution (250 mg/5 mL), capsules (100, 300, 400 mg), and tablets (600, 800 mg) are commercially available alongside Gralise and Horizant. Compounding of an essentially-a-copy preparation is restricted under FDA section 503A guidance; RonanRx compounds gabapentin only when the prescriber documents a patient-specific clinical reason that the manufactured product cannot meet, not for preference or price.
Safety signal
Risk of respiratory depression with concomitant opioids, benzodiazepines, or in older adults with renal impairment; FDA 2019 drug safety communication required new warnings. Misuse and diversion are documented at population scale.

Prescription review

Patient-Specific Prescription Only

Compounded Gabapentin on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.

  • Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
  • Named-patient label. The bottle carries your name. The batch records carry your prescription.
  • Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
  • Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
  • Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
For prescribing doctors Offer this medication → For patients Find a partner clinic →

Real medicine, not gray market

How This Differs from a Research-Use-Only Website

A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.

A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.

What it is

What is Compounded Gabapentin?

Gabapentin (1-(aminomethyl)cyclohexaneacetic acid) is a synthetic structural analog of γ-aminobutyric acid (GABA), originally developed at Parke-Davis as an anticonvulsant. Despite the GABA-mimetic design and trade name (Neurontin), gabapentin does not bind GABA-A or GABA-B receptors at therapeutic concentrations and is not converted to GABA in vivo at clinically meaningful rates. The molecule is a small zwitterionic amino acid taken up by the L-type amino acid transporter in the gut and across the blood-brain barrier, which produces saturable, dose-dependent oral absorption.

The FDA-approved manufactured products are Neurontin (immediate-release capsule 100, 300, 400 mg; tablet 600, 800 mg; oral solution 250 mg/5 mL; approved 1993), Gralise (gastric-retentive once-daily extended-release tablet 300, 600 mg; approved 2011 for postherpetic neuralgia), and Horizant (gabapentin enacarbil, an extended-release prodrug that is converted to gabapentin during intestinal absorption; tablet 300, 600 mg; approved 2011 for moderate-to-severe primary restless legs syndrome and 2012 expansion for postherpetic neuralgia) 31. The three products are not interchangeable: gastric-retentive Gralise and the gabapentin enacarbil prodrug Horizant differ from immediate-release Neurontin in bioavailability and dose-proportionality, and labels for each carry distinct titration schedules 30.

Compounded gabapentin is prepared on patient-specific prescription as (1) oral suspensions or solutions at custom strengths and excipient profiles when Neurontin 250 mg/5 mL is not clinically appropriate, (2) custom-strength capsules to support an individualized titration step or to exclude a sensitizing excipient, or (3) topical 6, 10% creams or gels for off-label localized neuropathic pain, a route and indication that is not commercially manufactured 2912.

How it works

How Compounded Gabapentin Works

Class
Anticonvulsant / GABA analog
First studied
FDA-approved 1993
Common forms
Compounded liquid, custom strength capsules
Compounding category
503A, patient-specific prescription

Gabapentin binds with high affinity to the α2δ-1 auxiliary subunit of voltage-gated calcium channels in the central nervous system 1. The α2δ-1 subunit modulates the trafficking and gating of high-voltage-activated (Ca_V) calcium channels in presynaptic terminals. Gabapentin binding reduces calcium influx during depolarization, decreasing the release of excitatory neurotransmitters, glutamate, substance P, calcitonin gene-related peptide, and noradrenaline, particularly in sensitized nociceptive pathways and in epileptogenic circuits with upregulated α2δ-1 expression 2.

Importantly, gabapentin is not a GABA receptor agonist. The naming reflects the molecule's GABA structural homology rather than its mechanism. Selective α2δ-1 ligand activity also distinguishes gabapentin and pregabalin from older anticonvulsants that act through sodium-channel blockade or direct GABA-A receptor potentiation. The clinical phenotype, anticonvulsant, antineuralgic, and anxiolytic effects with comparatively mild sedation and an absence of GABA-A withdrawal-style discontinuation, is consistent with the α2δ-1 mechanism.

Research history

Compounded Gabapentin Research History

Gabapentin was developed at Parke-Davis (later Warner-Lambert, now Pfizer) in the late 1970s and 1980s as a lipophilic GABA analog intended to cross the blood-brain barrier and to act as an anticonvulsant. The molecule was approved by FDA as Neurontin in December 1993 as adjunctive therapy for partial-onset seizures in adults, on the basis of the pivotal 1993 placebo-controlled studies (including the International Gabapentin Monotherapy Study Group; Chadwick 1998 Neurology 6 subsequently extended efficacy data to monotherapy) 29. The labeled indication was expanded to postherpetic neuralgia (PHN) in 2002 following the Rowbotham 1998 JAMA pivotal RCT 3, with Rice 2001 5 providing a second independent RCT, and the Backonja 1998 JAMA painful diabetic neuropathy RCT 4 establishing a parallel evidence base for off-label neuropathic pain indications.

Identification of the mechanism followed the clinical approval: Gee and colleagues (1996, J Biol Chem) 1 characterized gabapentin as a high-affinity ligand of an auxiliary subunit of voltage-gated calcium channels that was later identified as α2δ-1; the Sills 2006 mechanism review 2 integrated the subsequent α2δ literature 17. The SANAD partial-epilepsy unblinded RCT 7 placed gabapentin among the standard antiepileptic drugs for partial seizures alongside carbamazepine, lamotrigine, oxcarbazepine, and topiramate, with lamotrigine ranking favorably overall 29.

Off-label use accumulated through the 2000s and 2010s for generalized anxiety and social phobia 1213, fibromyalgia 9, hot flashes in breast cancer survivors 10, and alcohol use disorder 11. Perioperative gabapentin/pregabalin as adjuncts to multimodal analgesia was systematically reviewed by Tiippana and colleagues (2007) 18. The 2017 Cochrane review (Wiffen and colleagues) 8 is the standard meta-analytic synthesis for chronic neuropathic pain, reporting that gabapentin 1800, 3600 mg/day produces 50% pain reduction in approximately 30, 40% of patients with postherpetic neuralgia or painful diabetic peripheral neuropathy versus 10, 20% with placebo 16. Anticonvulsants (including gabapentin) for low back pain were demonstrated to be ineffective in a 2018 systematic review and meta-analysis 19, paralleled by the Mathieson 2017 NEJM pregabalin sciatica RCT 20 showing no benefit of the related gabapentinoid for sciatica 29.

Gralise (gastric-retentive once-daily gabapentin) was approved in January 2011 for postherpetic neuralgia 30; gabapentin enacarbil (Horizant) was approved in April 2011 for moderate-to-severe primary restless legs syndrome with a 2012 expansion to PHN, on the basis of phase 1, 3 PK/PD and efficacy studies 31 14. Misuse and diversion of gabapentin and gabapentinoids was systematically characterized by Smith and colleagues (2016, Addiction) 21 with practitioner commentary by Dunlop (2016) 22, population-scale opioid-mortality data by Gomes and colleagues (Ontario, 2017) 23, pharmacology review by Evoy and colleagues (2021) 25, and pharmacist/prescriber survey by Covvey and colleagues (2023) 26. Goodman and Brett (2019, JAMA Intern Med) published a clinical overview of off-label gabapentinoid use, and FDA issued a Drug Safety Communication in December 2019 32 adding warnings for respiratory depression with concomitant CNS depressants 24. Topical compounded gabapentin for localized neuropathic pain has been reported in case series and reviews 2728 15.

Timeline

Compounded Gabapentin Timeline

  1. 1993 FDA approves gabapentin as Neurontin (Parke-Davis) for adjunctive therapy of partial-onset seizures in adults 29
  2. 1996 Gee et al 1. characterize gabapentin as a high-affinity ligand of the α2δ subunit of voltage-gated calcium channels in J Biol Chem, mechanistic foundation for the α2δ-1 hypothesis
  3. 1998 Backonja et al. (JAMA) report the pivotal RCT of gabapentin for painful diabetic peripheral neuropathy; Rowbotham et al 43. (JAMA) report the pivotal RCT of gabapentin for postherpetic neuralgia
  4. 1998 Chadwick et al 6. (Neurology) report the International Gabapentin Monotherapy Study Group 945-77 trial in newly diagnosed partial seizures
  5. 1999 Pande et al 12. (J Clin Psychopharmacol), placebo-controlled trial of gabapentin for social phobia (social anxiety disorder)
  6. 2000 Pande et al 13. (J Clin Psychopharmacol), placebo-controlled trial of gabapentin for panic disorder
  7. 2001 Rice et al 5. (Pain), second independent RCT of gabapentin for postherpetic neuralgia at 1800 mg and 2400 mg/day
  8. 2002 FDA expands Neurontin labeling to include postherpetic neuralgia in adults 29
  9. 2005 Pandya et al 10. (Lancet), gabapentin for hot flashes in 420 women with breast cancer; dose-dependent reduction at 900 mg/day vs placebo
  10. 2006 Sills (Curr Opin Pharmacol) reviews the α2δ mechanism of action of gabapentin and pregabalin 2
  11. 2007 Arnold et al. (Arthritis Rheum), gabapentin RCT in fibromyalgia; Tiippana et al 9. (Anesth Analg) systematic review of perioperative gabapentin/pregabalin; Marson et al 187. (Lancet) SANAD unblinded RCT of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, and topiramate for partial epilepsy
  12. 2008 Boardman et al 27. (Obstet Gynecol), topical gabapentin for localized and generalized vulvodynia case series
  13. 2010 Cundy et al 17. (Int J Clin Pharmacol Ther) characterize food effect on gabapentin enacarbil pharmacokinetics, supports the dose-proportional absorption profile of the prodrug
  14. 2011 FDA approves Gralise (gastric-retentive once-daily gabapentin) for postherpetic neuralgia; FDA approves Horizant (gabapentin enacarbil prodrug) for moderate-to-severe primary restless legs syndrome 3031
  15. 2011 Lal et al 15. (Int J Clin Pharmacol Ther), phase 1 single-dose 14C-radiolabeled disposition study of gabapentin enacarbil
  16. 2012 Hayes et al 1431. (Ann Pharmacother) review gabapentin enacarbil for restless legs syndrome; FDA expands Horizant indication to postherpetic neuralgia
  17. 2013 Lal et al 16. (J Clin Pharmacol), population PK/PD of gabapentin after gabapentin enacarbil administration
  18. 2014 Mason et al 11. (JAMA Intern Med), gabapentin 1800 mg/day for alcohol use disorder; dose-dependent reduction in heavy drinking and craving
  19. 2016 Smith et al 2122. (Addiction), systematic review of gabapentin misuse, abuse, and diversion; Dunlop commentary follows in the same issue
  20. 2017 Wiffen et al. (Cochrane Database Syst Rev), updated meta-analysis of gabapentin for chronic neuropathic pain in adults; Gomes et al 828. (PLoS Med), Ontario population-based nested case-control of gabapentin + opioids and opioid-related death; Knezevic et al 23. (Pain Manag) review compounded topical analgesics including gabapentin
  21. 2017 Mathieson et al 20. (NEJM), Trial of Pregabalin for Acute and Chronic Sciatica reports no benefit, paralleling subsequent low-back-pain evidence
  22. 2018 Enke et al 19. (CMAJ), systematic review and meta-analysis of anticonvulsants (including gabapentin) for low back pain and lumbar radicular pain: no clinically meaningful benefit
  23. 2019 Goodman and Brett (JAMA Intern Med), clinical overview of off-label use of gabapentinoid drugs; FDA Drug Safety Communication (December 19, 2019) adds warnings for respiratory depression with concomitant CNS depressants or in older adults with compromised respiratory function 2432
  24. 2021 Evoy et al 25. (J Clin Pharmacol), review of gabapentinoid pharmacology in the context of emerging misuse liability
  25. 2023 Covvey et al 26. (Res Social Adm Pharm), pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse

Natural role

Biological Role of Compounded Gabapentin

Gabapentin is not an endogenous molecule. It is a synthetic small molecule developed to mimic GABA structurally and cross the blood-brain barrier, with a mechanism of action that turned out to be unrelated to GABAergic signaling. Its biological footprint is restricted to high-affinity binding at α2δ-1 (and to a lesser extent α2δ-2) auxiliary calcium channel subunits, with downstream reduction of presynaptic excitatory neurotransmission in pathologically sensitized or hyperactive neurons 12.

Clinical contexts studied

Clinical Contexts for Compounded Gabapentin

Adjunctive therapy for partial-onset seizures (adults and pediatric ≥3 years) fda approved

FDA-approved indication for Neurontin.

Gabapentin (Neurontin) is FDA-approved as adjunctive therapy for partial-onset seizures with or without secondary generalization in adults and pediatric patients ≥3 years 29. The International Gabapentin Monotherapy Study Group 945-77 trial 6 established monotherapy efficacy in newly diagnosed partial seizures, and the SANAD unblinded RCT 7 placed gabapentin among standard partial-epilepsy options alongside carbamazepine, lamotrigine, oxcarbazepine, and topiramate, with lamotrigine ranking favorably on the overall outcome composite.

Branded product: Neurontin (gabapentin, Pfizer)

Postherpetic neuralgia (PHN) in adults fda approved

FDA-approved indication for Neurontin, Gralise (once-daily gastric-retentive), and Horizant (gabapentin enacarbil).

Three FDA-approved manufactured products carry a PHN indication: Neurontin (titrated to 1800, 3600 mg/day in three divided doses), Gralise (titrated to 1800 mg once daily with the evening meal), and Horizant (gabapentin enacarbil 600 mg twice daily) 293031. The pivotal evidence is Rowbotham 1998 JAMA 3 reporting a 33% reduction in average daily pain score with gabapentin 3600 mg/day vs 7.7% with placebo at 8 weeks, replicated by Rice 2001 Pain 5 at 1800 mg/day and 2400 mg/day. The 2017 Cochrane meta-analysis 8 reports that approximately 30, 40% of patients with PHN or painful diabetic peripheral neuropathy achieve 50% pain reduction on gabapentin 1800, 3600 mg/day vs 10, 20% with placebo.

Branded product: Neurontin, Gralise, Horizant

Moderate-to-severe primary restless legs syndrome (RLS) in adults fda approved

FDA-approved indication for Horizant (gabapentin enacarbil).

Gabapentin enacarbil (Horizant) is FDA-approved for moderate-to-severe primary RLS in adults at a maintenance dose of 600 mg once daily, taken at approximately 5 pm 31. The phase 1 disposition study 15 and population PK/PD analysis 16 supported the once-daily dosing, and the Hayes 2012 review 14 consolidated efficacy and safety. The food-effect study 17 characterizes the high-fat-meal sensitivity of the prodrug. Immediate-release gabapentin (Neurontin) is also used off-label for RLS but is not FDA-approved for this indication.

Branded product: Horizant (gabapentin enacarbil, Arbor Pharmaceuticals)

Painful diabetic peripheral neuropathy well studied

Off-label for gabapentin but supported by pivotal randomized evidence and standard meta-analytic synthesis.

Backonja 1998 JAMA 4 randomized 165 adults with painful diabetic peripheral neuropathy to gabapentin titrated to 3600 mg/day or placebo for 8 weeks and reported a mean daily pain score reduction of 2.5 vs 1.4 on the 11-point numerical rating scale. The Wiffen 2017 Cochrane review 8 places painful diabetic peripheral neuropathy in the same efficacy band as postherpetic neuralgia for gabapentin. Note that gabapentin does not have an FDA indication for painful diabetic peripheral neuropathy; pregabalin (Lyrica) and duloxetine do.

Generalized anxiety, social anxiety disorder, and panic disorder well studied

Off-label; supported by placebo-controlled trials but not FDA-approved.

Pande and colleagues reported placebo-controlled trials of gabapentin for social phobia (1999) 12 and panic disorder (2000) 13 in the Journal of Clinical Psychopharmacology, demonstrating dose-dependent reduction in symptom scores. Gabapentin is not FDA-approved for any anxiety disorder; pregabalin carries a generalized anxiety disorder indication in Europe but not in the United States.

Alcohol use disorder well studied

Off-label; supported by a randomized clinical trial in JAMA Internal Medicine.

Mason and colleagues (2014, JAMA Internal Medicine) 11 randomized 150 adults with alcohol dependence to gabapentin 900 mg/day, gabapentin 1800 mg/day, or placebo for 12 weeks and reported a dose-dependent increase in abstinence and no-heavy-drinking days, with the 1800 mg/day arm achieving complete abstinence in 17% (vs 4% on placebo, NNT 8) and no heavy drinking in 45% (vs 23% placebo, NNT 5). Gabapentin is not FDA-approved for alcohol use disorder; naltrexone, acamprosate, and disulfiram are.

Hot flashes (vasomotor symptoms) in breast cancer survivors well studied

Off-label; supported by a Lancet randomized trial.

Pandya and colleagues (2005, Lancet) 10 randomized 420 women with breast cancer and ≥2 hot flashes/day to gabapentin 300 mg/day, gabapentin 900 mg/day, or placebo for 8 weeks. The 900 mg/day arm reduced hot-flash severity score by 46% vs 15% with placebo. The 300 mg/day arm was not significantly different from placebo. Gabapentin is not FDA-approved for vasomotor symptoms.

Fibromyalgia well studied

Off-label; supported by a phase 2 randomized trial.

Arnold and colleagues (2007, Arthritis & Rheumatism) 9 randomized 150 adults with fibromyalgia to gabapentin titrated to 1200, 2400 mg/day or placebo for 12 weeks and reported a 51% reduction in the Brief Pain Inventory average pain severity score with gabapentin vs 31% with placebo. Gabapentin is not FDA-approved for fibromyalgia; pregabalin, duloxetine, and milnacipran carry the indication.

Chronic neuropathic pain (mixed etiologies) well studied

Off-label for non-PHN indications; standard meta-analytic synthesis is the 2017 Cochrane review.

The Wiffen 2017 Cochrane review of gabapentin for chronic neuropathic pain in adults 8 pooled 37 studies (>5,900 participants) and reported moderate-quality evidence that gabapentin at 1800, 3600 mg/day produces 50% or greater pain reduction in approximately 30, 40% of patients with postherpetic neuralgia or painful diabetic peripheral neuropathy versus 10, 20% with placebo (NNT approximately 6, 8). Evidence in other neuropathic pain conditions is limited.

Perioperative multimodal analgesia well studied

Off-label; mixed evidence with safety signal of post-operative sedation and respiratory depression in opioid-naïve patients.

Tiippana and colleagues (2007, Anesthesia & Analgesia) 18 systematically reviewed perioperative gabapentin and pregabalin and reported modest opioid-sparing effects with increased sedation. Subsequent FDA labeling and 2019 safety communication 32 caution about respiratory depression when gabapentinoids are combined with opioids, including in the perioperative period.

Localized neuropathic pain, topical 6, 10% compounded cream or gel emerging

Off-label and not commercially available; small case series and topical-analgesic reviews; evidence remains limited.

Boardman and colleagues (2008, Obstet Gynecol) 27 reported a case series of topical 2, 6% gabapentin for localized and generalized vulvodynia, with symptomatic improvement in the majority of patients. The Knezevic 2017 review of compounded topical analgesics 28 consolidated case-series evidence for topical gabapentin alone or combined with ketamine, amitriptyline, lidocaine, or baclofen in localized neuropathic pain. The evidence base is small, single-arm or open-label, and the route is not commercially manufactured; topical compounded gabapentin remains a tier 2, 3 off-label option for localized peripheral neuropathic pain when systemic therapy is poorly tolerated or contraindicated.

Off-label use

Off-Label Uses of Compounded Gabapentin

Low back pain and lumbar radicular pain (sciatica) well studied

Off-label; randomized evidence does not support clinically meaningful benefit.

Enke and colleagues (2018, CMAJ) 19 systematically reviewed nine RCTs (859 participants) of anticonvulsants for low back pain and lumbar radicular pain and concluded that gabapentin and pregabalin do not produce clinically meaningful benefit and increase adverse events. Mathieson and colleagues (2017, NEJM) 20 randomized 209 adults with sciatica to pregabalin or placebo and found no benefit at 8 or 52 weeks. Gabapentinoids should not be used routinely for low back pain or sciatica.

FDA-approved use

FDA-Approved Uses of Compounded Gabapentin

BrandIndicationYearRoute
Neurontin Adjunctive therapy for partial-onset seizures in adults and pediatric patients ≥3 years; postherpetic neuralgia in adults 1993 Oral capsule (100, 300, 400 mg), tablet (600, 800 mg), and oral solution (250 mg/5 mL)
Gralise Postherpetic neuralgia in adults, once-daily gastric-retentive extended-release tablet 2011 Oral tablet (300, 600 mg), titrated to 1800 mg once daily with the evening meal
Horizant Moderate-to-severe primary restless legs syndrome in adults (2011); postherpetic neuralgia in adults (2012) 2011 Oral extended-release tablet of the gabapentin enacarbil prodrug (300, 600 mg)

Three FDA-approved manufactured gabapentin products are commercially available in the United States: Neurontin (Pfizer; approved December 30, 1993), Gralise (Almatica/Assertio; approved January 28, 2011), and Horizant (gabapentin enacarbil, Arbor Pharmaceuticals; approved April 6, 2011, with a postherpetic neuralgia expansion in 2012). The three products are not interchangeable: Gralise is a gastric-retentive once-daily formulation that requires administration with the evening meal, and Horizant is a prodrug (gabapentin enacarbil) that is absorbed across the entire small intestine and colon and converted to gabapentin during absorption, producing dose-proportional pharmacokinetics that immediate-release Neurontin does not 3031.

Generic immediate-release gabapentin (capsule, tablet, and oral solution at 250 mg/5 mL) has been widely available since the early 2000s; AB-rated generics for Gralise and Horizant are also available 29. Compounded gabapentin is not FDA-approved and is restricted under section 503A to patient-specific clinical needs that the manufactured products cannot meet 33.

Compounded use

Compounded Compounded Gabapentin (503A)

Compounded gabapentin is dispensed under 503A only when the prescribing clinician documents a patient-specific clinical need that the manufactured Neurontin, Gralise, or Horizant products cannot meet 3031. Because immediate-release gabapentin is commercially available as Neurontin oral solution (250 mg/5 mL), capsules at 100/300/400 mg, and tablets at 600/800 mg, the threshold for compounding an essentially-a-copy oral preparation is high and the prescriber's clinical reason must be specific 33.

Documented compounding indications at RonanRx fall into three primary categories. First, pediatric or adult dysphagia oral suspensions at custom strengths or excipient profiles when the commercial 250 mg/5 mL oral solution is not appropriate, for example, when the patient requires a strength outside the commercial concentration to support precise mg/kg dosing or to limit volume in a fluid-restricted patient, or when the patient has a documented sensitivity to a sweetener, preservative, dye, or flavoring in the commercial solution. Second, custom-strength solid oral preparations to support an individualized titration step (for example, 50 mg or 200 mg capsules not commercially available) or to exclude a sensitizing excipient, these are restricted under the FDA essentially-a-copy guidance and require explicit prescriber documentation. Third, topical 6, 10% gabapentin creams or gels, sometimes combined with other agents per prescriber direction, for off-label localized peripheral neuropathic pain (post-amputation neuroma, postsurgical neuropathic pain in a localized distribution, vulvodynia 27, or other small-area neuropathic conditions); the topical route is not commercially manufactured and is therefore not subject to the essentially-a-copy restriction 28 30.

Compounded preparations are not bioequivalent to the manufactured products. Compounded oral suspensions and capsules should be assumed to follow the saturable, dose-dependent absorption profile of immediate-release gabapentin, with bioavailability falling from approximately 60% at 300 mg to ~35% at 1600 mg per dose 29. Topical 6, 10% gabapentin preparations have not been characterized for systemic absorption in formal pharmacokinetic studies, and clinicians should not assume the systemic-route safety profile transfers; per-patient assessment of localized response is the primary endpoint, and the pharmacist's batch documentation supports traceability of strength, excipient, and beyond-use date 30.

Misuse and diversion of gabapentin are documented at population scale 212526 and combination with opioids is associated with increased risk of opioid-related death 23. FDA's December 2019 Drug Safety Communication 32 added warnings for serious breathing problems with concomitant CNS depressants, in older adults, and in patients with compromised respiratory function. RonanRx pharmacist review explicitly evaluates concomitant medication risk before dispensing compounded gabapentin 30.

Formulations and routes

Compounded Gabapentin Formulations and Routes

FormConcentrationDescription
Compounded oral suspension or solution Custom, typically 50 mg/mL or 100 mg/mL, with patient-specific excipient profile (no dye, no sucrose, no specified flavoring, etc.) Patient-specific oral liquid prepared under USP <795> standards for nonsterile compounding when the commercial Neurontin oral solution (250 mg/5 mL) is not clinically appropriate. Container closure, excipient profile, beyond-use date, and stability basis are documented per batch.35
Compounded custom-strength capsule Custom, typical patient-specific strengths between 25 mg and 250 mg for individualized titration steps not commercially available Patient-specific solid oral preparation when the commercial 100, 300, 400, 600, or 800 mg strengths do not support the prescriber's titration plan or when the patient requires exclusion of a sensitizing excipient (dye, gluten, lactose, specific flavoring). Restricted under FDA essentially-a-copy guidance.3533
Compounded topical cream or gel Typically 6% or 10% gabapentin; combination preparations per prescriber direction Topical preparation for off-label localized peripheral neuropathic pain (post-amputation neuroma, postsurgical neuropathic pain in a localized distribution, vulvodynia, or small-area neuropathic conditions). Route is not commercially manufactured and is not subject to essentially-a-copy restriction. Evidence base is small case series and topical-analgesic reviews.352728
Manufactured immediate-release capsule, tablet, oral solution (reference product) Neurontin 100, 300, 400 mg capsule; 600, 800 mg tablet; 250 mg/5 mL oral solution FDA-approved manufactured Neurontin (Pfizer) and AB-rated generics. Titrated to 1800, 3600 mg/day in three divided doses for adult indications.29
Manufactured gastric-retentive extended-release tablet (reference product) Gralise 300, 600 mg tablet; titrated to 1800 mg once daily with the evening meal FDA-approved manufactured Gralise (Almatica/Assertio) for postherpetic neuralgia in adults.30
Manufactured gabapentin enacarbil extended-release tablet (reference product) Horizant 300, 600 mg tablet of gabapentin enacarbil prodrug; 600 mg once daily for restless legs syndrome, 600 mg twice daily for postherpetic neuralgia FDA-approved manufactured Horizant (gabapentin enacarbil, Arbor Pharmaceuticals). Prodrug actively transported across the entire small intestine and colon; produces dose-proportional gabapentin exposure.311516

Routes used in published literature: oral, topical.

Dosing

Compounded Gabapentin Dosing

RoutePopulationRangeDurationStudy type
Oral Adults with postherpetic neuralgia (Neurontin labeled regimen) Day 1: 300 mg; day 2: 600 mg in 2 divided doses; day 3: 900 mg in 3 divided doses; then titrate as needed to 1800 mg/day in 3 divided doses. Maximum studied dose: 3600 mg/day. Indefinite while clinically beneficial FDA-approved labeled regimen293
Oral Adults with partial-onset seizures (Neurontin labeled regimen, adjunctive) Initiate at 300 mg three times daily; titrate to 900, 1800 mg/day in 3 divided doses. Doses up to 2400 mg/day used long-term; 3600 mg/day tolerated short-term. Indefinite while clinically beneficial FDA-approved labeled regimen296
Oral Pediatric patients 3, 12 years with partial seizures (Neurontin labeled regimen) Initiate at 10, 15 mg/kg/day in 3 divided doses; titrate over approximately 3 days to effective dose. For 3, 4 year-olds, effective dose is 40 mg/kg/day; for 5, 12 year-olds, 25, 35 mg/kg/day. Indefinite while clinically beneficial FDA-approved labeled regimen29
Oral Adults with postherpetic neuralgia (Gralise labeled regimen) Day 1: 300 mg; day 2: 600 mg; day 3: 900 mg; day 4: 1200 mg; day 5: 1500 mg; day 6 onwards: 1800 mg once daily with the evening meal. Indefinite while clinically beneficial FDA-approved labeled regimen30
Oral Adults with moderate-to-severe primary restless legs syndrome (Horizant labeled regimen) 600 mg once daily at approximately 5 pm. Doses above 600 mg/day do not provide additional benefit and increase adverse events. Indefinite while clinically beneficial FDA-approved labeled regimen3114
Oral Adults with postherpetic neuralgia (Horizant labeled regimen) Day 1, 3: 600 mg once daily in the morning; day 4 onwards: 600 mg twice daily (morning and afternoon). Indefinite while clinically beneficial FDA-approved labeled regimen31
Oral Adults with painful diabetic peripheral neuropathy (off-label) Titrate as for postherpetic neuralgia to 1800, 3600 mg/day in 3 divided doses 8 weeks in the pivotal trial; longer use as clinically indicated Phase 3 RCT (off-label)48
Oral Adults with alcohol use disorder (off-label) Gabapentin titrated to 1800 mg/day in 3 divided doses (900 mg/day arm also studied) 12 weeks in the pivotal trial Phase 2 RCT (off-label)11
Oral Women with breast cancer and hot flashes (off-label) 900 mg/day in 3 divided doses (300 mg/day arm not significantly different from placebo) 8 weeks in the pivotal trial Phase 3 RCT (off-label)10
Topical Adults with localized peripheral neuropathic pain (off-label, compounded) Typically 6, 10% gabapentin cream or gel applied to the localized area three to four times daily; no labeled regimen Per prescriber direction; reassess at 4, 8 weeks Case series and topical-analgesic reviews (off-label)2728

Doctor-prescribed and titrated. Immediate-release gabapentin must be titrated upward over days because of dose-limiting sedation and dizziness during initiation; the labeled PHN escalation moves from 300 mg on day 1 to 1800 mg/day in 3 divided doses by approximately day 7 30. Dose adjustment for renal impairment is required: at creatinine clearance 30, 59 mL/min, maximum daily dose is approximately 1400 mg; at 15, 29 mL/min, 700 mg; at <15 mL/min, 300 mg; and supplemental dosing is required after hemodialysis. Older adults are at increased risk of CNS adverse events and respiratory depression and warrant cautious initiation 2932.

Compounded preparations should mirror manufactured-product dosing unless the prescriber documents a patient-specific reason for variance. Gabapentin enacarbil (Horizant) cannot be substituted milligram-for-milligram for immediate-release gabapentin because of fundamentally different pharmacokinetics 151617, and compounded preparations should not be cross-titrated from one manufactured product to another without explicit prescriber direction 31. Topical 6, 10% compounded gabapentin has no labeled regimen and is dosed per prescriber direction with reassessment at 4, 8 weeks 30.

Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.

Safety

Compounded Gabapentin Safety

Safety overview

Gabapentin's safety is dominated by central nervous system adverse events, somnolence, dizziness, fatigue, ataxia, and peripheral edema, that are dose-dependent and concentrated in the titration period. Rates in the Wiffen 2017 Cochrane review 8 are approximately: somnolence 14, 22%, dizziness 19, 29%, peripheral edema 7, 8%, and gait disturbance 9% on gabapentin 1800, 3600 mg/day vs ~5, 8% on placebo. Adverse-event-driven discontinuation in chronic neuropathic pain trials runs 11, 13% on gabapentin vs ~9% on placebo.

Respiratory depression is the most clinically consequential safety concern. FDA's December 19, 2019 Drug Safety Communication 32 required new warnings on all gabapentinoid labels regarding serious breathing problems in patients using gabapentin with opioids or other CNS depressants, in patients with underlying respiratory impairment, and in elderly patients. Population-based Ontario data 23 23 reported that concomitant gabapentin and opioid use was associated with a 49% increase in opioid-related death (adjusted odds ratio 1.49; 95% CI 1.18, 1.88) compared with opioid use alone, with a dose-response gradient.

Misuse, abuse, and diversion are documented. Smith and colleagues (2016, Addiction) 21 systematically reviewed misuse and reported that gabapentin is misused for its sedative and euphorigenic effects, particularly among opioid-using populations, with prevalence of misuse in selected populations as high as 15, 22%; commentary by Dunlop (2016) 22 noted the clinical implications. Evoy and colleagues (2021, J Clin Pharmacol) reviewed the pharmacology of misuse liability 25 and Covvey and colleagues (2023) 26 surveyed pharmacist, prescriber, and policy expert opinions. As of 2026, gabapentin remains a non-controlled medication federally in the United States but is a scheduled drug in several states 293031.

Other notable considerations include weight gain (in chronic neuropathic pain and anticonvulsant use), DRESS (drug reaction with eosinophilia and systemic symptoms; rare), suicidality (anticonvulsant class warning), and serious dermatologic reactions (rare). Gabapentin is generally well tolerated in older adults at appropriately reduced doses for renal function, but the increased risk of falls and confusion at any given exposure makes geriatric dose individualization important 24. Manufactured-product safety data summarized here cannot be assumed to translate without modification to compounded preparations that differ in concentration, excipient profile, or route (especially topical), and FAERS pharmacovigilance evidence specific to compounded gabapentin is limited.

Contraindications

Gabapentin is contraindicated only in patients with known hypersensitivity to gabapentin or any product excipient per the manufactured-product labels. For gabapentin enacarbil (Horizant), additional contraindications include hypersensitivity to gabapentin enacarbil 31 2930.

Precautions include renal impairment (dose adjustment required), concomitant CNS depressants (opioids, benzodiazepines, alcohol) given the respiratory-depression signal 32, older adults with compromised respiratory function, history of substance use disorder (given the documented misuse and diversion signal 2125), and pregnancy (limited human data; potential developmental risk reported in animal studies) 29. Suicidal ideation and behavior have been reported with anticonvulsants as a class.

Drug interactions

Gabapentin is not metabolized by cytochrome P450 enzymes, is not protein-bound, and does not participate in CYP-mediated drug-drug interactions. The principal clinically important interactions are pharmacodynamic: additive sedation and respiratory depression with opioids, benzodiazepines, alcohol, and other CNS depressants 3223. Antacids containing aluminum and magnesium reduce gabapentin bioavailability by approximately 20% if taken simultaneously; gabapentin should be administered at least 2 hours after antacid 29.

Morphine increases gabapentin AUC by approximately 44% per labeling; this is clinically relevant given the additive respiratory depression risk. Hydrocodone exposure is reduced by gabapentin co-administration in a dose-dependent fashion. Patients on combination opioid and gabapentin regimens should be monitored for sedation and respiratory depression, and the combination should be avoided or minimized where clinically possible 3223 293031.

Adverse events

Across the pivotal Neurontin trials in postherpetic neuralgia 35, painful diabetic peripheral neuropathy 4, and partial seizures 6, and the Cochrane 2017 meta-analysis 8, the most common adverse events with gabapentin vs placebo were somnolence (14, 27%), dizziness (19, 29%), peripheral edema (7, 17%), ataxia/gait disturbance (3, 9%), fatigue (5, 11%), and nausea (4, 8%). Adverse-event-driven discontinuation in chronic neuropathic pain trials ran 11, 13% on gabapentin vs ~9% on placebo per the Cochrane synthesis 8. Fibromyalgia trial discontinuation rates were similar 9, and the alcohol-use-disorder trial reported tolerability comparable to placebo at 1800 mg/day 11.

Serious adverse events specific to gabapentinoids include respiratory depression with concomitant CNS depressants 3223, DRESS, multi-organ hypersensitivity, suicidality (anticonvulsant class effect), and rare angioedema. Misuse, abuse, and diversion are documented at population scale 212526 and FAERS pharmacovigilance for compounded gabapentin in particular is limited; pharmacist review at dispensing is the principal mitigation.

Monitoring

Monitoring Compounded Gabapentin Therapy

Baseline assessment should include renal function (serum creatinine and creatinine clearance), concomitant medication review with particular attention to opioids, benzodiazepines, and other CNS depressants, screening for history of substance use disorder, and reproductive plans in patients of childbearing potential. In older adults, baseline assessment of fall risk and respiratory reserve is appropriate.

On therapy: tolerability assessment at each titration step; renal function periodically (especially in older adults and patients with chronic kidney disease); indication-specific response (pain score, seizure frequency, RLS symptom severity) at 4 and 8 weeks; review of concomitant CNS depressants and signs of misuse or sedation 32. Patients should be educated to recognize and report excessive sedation, slowed breathing, mood or behavior changes, and unusual rash 293031.

Special populations

Compounded Gabapentin in Special Populations

Pregnancy

Limited human data; animal studies have shown developmental toxicity. The North American Antiepileptic Drug Pregnancy Registry has accumulated outcome data on gabapentin exposure in pregnancy with no clear teratogenic signal but reports remain limited 293031. Use during pregnancy only when potential benefit justifies the potential risk per the manufactured-product labels; coordinate prescribing with the patient's obstetrician.

Lactation

Gabapentin is present in human milk at low concentrations (relative infant dose typically <5%); breastfed infants have not shown consistent adverse effects in case series. The developmental and health benefits of breastfeeding should be considered alongside the patient's clinical need for gabapentin per the manufactured-product labels 293031.

Pediatric

Neurontin is FDA-approved as adjunctive therapy for partial-onset seizures in pediatric patients ≥3 years at weight-based dosing (10, 15 mg/kg/day initial, titrated to 25, 40 mg/kg/day per age) 29. Neurontin is not FDA-approved for postherpetic neuralgia in pediatric patients, and Gralise and Horizant are not FDA-approved in pediatric patients. Compounded oral suspensions are a common 503A use case in pediatrics when the commercial 250 mg/5 mL solution is not appropriate (custom strength for mg/kg dosing, excipient sensitivity, or fluid restriction).

Geriatric

Older adults are at increased risk of CNS adverse events, falls, and respiratory depression on gabapentin, particularly with concomitant opioids or benzodiazepines 3224 29. Dose reduction for age-related decline in renal clearance is appropriate per labeled renal-impairment titration; concomitant CNS depressants should be minimized where clinically possible.

Renal impairment

Gabapentin is eliminated unchanged in the urine with clearance proportional to creatinine clearance. Dose adjustment is required: at CrCl 30, 59 mL/min, maximum total daily dose approximately 1400 mg; at 15, 29 mL/min, 700 mg; at <15 mL/min, 300 mg; and supplemental 125, 350 mg dose after each hemodialysis session per manufactured-product labels 29. Gabapentin enacarbil (Horizant) labeling specifies different renal-adjustment thresholds 31.

Hepatic impairment

Gabapentin is not hepatically metabolized; no dose adjustment is required for hepatic impairment per the manufactured-product labels 293031.

Evidence quality

Compounded Gabapentin Evidence Quality

Evidence supporting manufactured Neurontin, Gralise, and Horizant is mature: pivotal randomized trials in postherpetic neuralgia 3 and partial seizures 6 supported the original Neurontin approvals, with subsequent phase 3 evidence for Gralise (gastric-retentive) and the Horizant prodrug program 5. The Cochrane 2017 systematic review and meta-analysis of gabapentin for chronic neuropathic pain in adults (37 studies, >5,900 participants) 8 is the standard meta-analytic synthesis 1421. Off-label evidence is large and variable in quality: pivotal RCTs support painful diabetic peripheral neuropathy 4, alcohol use disorder 11, hot flashes in breast cancer survivors 10, fibromyalgia 9, and anxiety disorders 1213, while randomized evidence does not support routine use for low back pain or sciatica 1920.

Evidence specifically supporting compounded preparations is limited 2526. Oral suspensions and capsules can be expected to follow the saturable, dose-dependent absorption profile of immediate-release gabapentin 29 but compounded preparations are not bioequivalent to Neurontin and have not been characterized in formal PK studies 1732. Topical 6, 10% compounded gabapentin for localized neuropathic pain is supported by small case series 27 and topical-analgesic reviews 28 but has not been studied in adequately powered randomized trials and remains a tier 2, 3 off-label option 23. Post-marketing safety considerations specific to the compounded supply chain include the same misuse, diversion, and concomitant-CNS-depressant respiratory-depression risks documented for manufactured gabapentin, plus the compounding-specific risks of dose-strength errors and excipient variability that any 503A preparation introduces 7 1516.

Major studies

Major Compounded Gabapentin Clinical Studies

StudyDesignParticipantsDurationFinding
Rowbotham et al. (1998, JAMA), Pivotal RCT in postherpetic neuralgia Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of gabapentin titrated to 3600 mg/day vs placebo in adults with postherpetic neuralgia 229 8 weeks Average daily pain score reduced by 33% (from 6.3 to 4.2) on gabapentin vs 7.7% on placebo (P<0.001); supported the 2002 FDA expansion of the Neurontin label to PHN 3
Rice et al. (2001, Pain), Second independent PHN RCT Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of gabapentin 1800 mg/day or 2400 mg/day vs placebo in adults with postherpetic neuralgia 334 7 weeks Mean weekly pain score reduced significantly more on gabapentin 1800 mg/day (−34.5%) and 2400 mg/day (−34.4%) vs placebo (−15.7%); replicates the Rowbotham 1998 effect at lower target doses 5
Backonja et al. (1998, JAMA), Pivotal RCT in painful diabetic peripheral neuropathy Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of gabapentin titrated to 3600 mg/day vs placebo in adults with painful diabetic peripheral neuropathy 165 8 weeks Mean daily pain score reduced from 6.4 to 3.9 on gabapentin vs 6.5 to 5.1 on placebo (P<0.001); standard off-label evidence base for gabapentin in painful diabetic peripheral neuropathy (gabapentin not FDA-approved for this indication) 4
Chadwick et al. (1998, Neurology), Monotherapy in newly diagnosed partial seizures Phase 3, randomized, double-blind trial of gabapentin monotherapy in adults with newly diagnosed partial seizures (International Gabapentin Monotherapy Study Group 945-77) 292 26 weeks Gabapentin 900, 1200, and 1800 mg/day produced comparable efficacy to active comparator, supporting partial-onset seizure efficacy as monotherapy 6
Marson et al. (2007, Lancet), SANAD partial epilepsy arm Unblinded randomized controlled trial of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, and topiramate for treatment of partial-onset epilepsy 1721 Up to 4 years follow-up Gabapentin was inferior to lamotrigine on time-to-treatment-failure and time-to-12-month-remission composite outcomes; informs comparative effectiveness positioning of gabapentin in partial epilepsy 7
Wiffen et al. (2017, Cochrane Database Syst Rev), Standard chronic neuropathic pain meta-analysis Updated Cochrane systematic review and meta-analysis of gabapentin for chronic neuropathic pain in adults 5914 (37 studies) 4, 14 weeks pooled Gabapentin at 1800, 3600 mg/day produces 50% or greater pain reduction in approximately 30, 40% of patients with postherpetic neuralgia or painful diabetic peripheral neuropathy vs 10, 20% with placebo (NNT ≈ 6, 8) 8. Moderate-quality evidence. Adverse-event-driven discontinuation 11, 13% on gabapentin vs ~9% placebo.
Mason et al. (2014, JAMA Internal Medicine), Gabapentin for alcohol use disorder Phase 2 randomized, double-blind, placebo-controlled trial of gabapentin 900 mg/day vs 1800 mg/day vs placebo in adults with alcohol dependence 150 12 weeks Dose-dependent increase in complete abstinence (4%, 11%, 17% on placebo, 900 mg, 1800 mg) and no-heavy-drinking days (23%, 30%, 45%); NNT 8 for abstinence and 5 for no heavy drinking at 1800 mg/day 11
Pandya et al. (2005, Lancet), Gabapentin for hot flashes in breast cancer Phase 3 randomized, double-blind, placebo-controlled, three-arm trial of gabapentin 300 mg/day vs 900 mg/day vs placebo in women with breast cancer and ≥2 hot flashes/day 420 8 weeks Hot flash severity score reduced by 46% on 900 mg/day vs 15% on placebo (P<0.001). The 300 mg/day arm did not differ significantly from placebo 10.
Arnold et al. (2007, Arthritis & Rheumatism), Gabapentin for fibromyalgia Phase 2 randomized, double-blind, placebo-controlled, multicenter trial of gabapentin 1200, 2400 mg/day vs placebo in adults with fibromyalgia 150 12 weeks 51% of gabapentin-treated patients achieved 30% or greater improvement in Brief Pain Inventory average pain severity score vs 31% on placebo; modest tolerability issues at the higher dose range 9
Pande et al. (1999, J Clin Psychopharmacol), Gabapentin for social phobia Phase 2 randomized, double-blind, placebo-controlled trial of gabapentin titrated to 900, 3600 mg/day vs placebo in adults with social phobia (social anxiety disorder) 69 14 weeks Gabapentin reduced Liebowitz Social Anxiety Scale scores more than placebo; supports off-label use in social anxiety disorder (not FDA-approved for any anxiety indication) 12
Pande et al. (2000, J Clin Psychopharmacol), Gabapentin for panic disorder Phase 2 randomized, double-blind, placebo-controlled trial of gabapentin titrated to 600, 3600 mg/day vs placebo in adults with panic disorder 103 8 weeks No overall benefit on the Panic and Agoraphobia Scale; pre-specified subgroup of more severely ill patients showed improvement on gabapentin 13
Gee et al. (1996, J Biol Chem), Mechanism of action discovery Radioligand binding and biochemical characterization of gabapentin binding in porcine brain membranes — — Identified gabapentin as a high-affinity ligand of an auxiliary calcium channel subunit subsequently identified as α2δ-1; foundational mechanism paper 1
Sills (2006, Curr Opin Pharmacol), Mechanism review Narrative review of α2δ-mediated mechanism of action for gabapentin and pregabalin — — Consolidates the α2δ-1 binding evidence and downstream effects on presynaptic calcium influx and excitatory neurotransmitter release; standard mechanism reference 2
Lal et al. (2011, Int J Clin Pharmacol Ther), Gabapentin enacarbil 14C disposition Phase 1 single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers 6 Single dose Characterized the absorption, conversion to gabapentin, and elimination of the gabapentin enacarbil prodrug; supports the dose-proportional PK that distinguishes Horizant from immediate-release Neurontin 15
Lal et al. (2013, J Clin Pharmacol), Population PK/PD of gabapentin enacarbil Population pharmacokinetic and pharmacodynamic analysis after gabapentin enacarbil administration across phase 1 and phase 3 RLS programs — — Linear dose-proportional gabapentin exposure after enacarbil prodrug administration; supports once-daily 600 mg dosing for RLS and twice-daily 600 mg for postherpetic neuralgia 16
Hayes et al. (2012, Ann Pharmacother), Gabapentin enacarbil for RLS review Review of efficacy, safety, and pharmacology of gabapentin enacarbil (Horizant) for restless legs syndrome — — 600 mg once daily is the optimal labeled dose for moderate-to-severe primary RLS; doses above 600 mg/day do not add benefit 14
Cundy et al. (2010, Int J Clin Pharmacol Ther), Food effect on gabapentin enacarbil Phase 1 randomized crossover study of food effect on gabapentin enacarbil pharmacokinetics — — Gabapentin exposure increases with food fat content; supports the Horizant labeling requirement to administer with food 17
Tiippana et al. (2007, Anesth Analg), Perioperative gabapentinoids review Systematic review of perioperative gabapentin and pregabalin for postoperative analgesia and opioid sparing — — Modest opioid-sparing effects with increased sedation; informed subsequent FDA labeling on perioperative respiratory depression 18
Enke et al. (2018, CMAJ), Anticonvulsants for low back pain meta-analysis Systematic review and meta-analysis of nine RCTs of anticonvulsants (including gabapentin and pregabalin) for low back pain and lumbar radicular pain 859 Pooled trial durations Gabapentinoids do not produce clinically meaningful benefit for low back pain or sciatica and increase adverse events; argues against routine use 19
Mathieson et al. (2017, NEJM), Pregabalin for sciatica Phase 3 randomized double-blind placebo-controlled trial of pregabalin (gabapentinoid class) for acute and chronic sciatica 209 8 weeks treatment, 52 weeks follow-up No benefit on leg-pain intensity at 8 or 52 weeks; supports the negative conclusion of the Enke 2018 meta-analysis for the gabapentinoid class in radicular pain 20
Smith et al. (2016, Addiction), Misuse, abuse, and diversion systematic review Systematic review of gabapentin misuse, abuse, and diversion in clinical and general populations — — Misuse documented particularly among opioid-using populations with prevalence as high as 15, 22% in selected subgroups; informed subsequent state scheduling decisions and FDA safety communications 21
Gomes et al. (2017, PLoS Med), Gabapentin + opioid mortality (Ontario) Population-based nested case-control study of opioid users in Ontario, Canada 1256 cases, 4619 controls 1997, 2013 Concomitant gabapentin and opioid use was associated with a 49% increase in the odds of opioid-related death (adjusted OR 1.49, 95% CI 1.18, 1.88) vs opioid use alone, with a dose-response gradient 23
Goodman & Brett (2019, JAMA Internal Medicine), Off-label gabapentinoid use overview Clinical overview of off-label use of gabapentinoid drugs in the United States — — Documents wide off-label use, much of it not supported by adequate evidence; calls for more conservative prescribing and renewed attention to misuse and respiratory depression risk 24
Evoy et al. (2021, J Clin Pharmacol), Gabapentinoid misuse pharmacology Review of gabapentinoid pharmacology in the context of emerging misuse liability — — Characterizes the pharmacologic substrate (CNS sedation, opioid potentiation) for misuse and recommends pharmacist-level interventions at dispensing 25
Covvey et al. (2023, Res Social Adm Pharm), Pharmacist and prescriber survey Mixed-methods survey of pharmacist, prescriber, and drug-policy expert opinions on gabapentinoid misuse and policy responses — — Substantial concern across stakeholders about misuse and diversion, with widespread support for pharmacist-level screening and selective state scheduling 26
Boardman et al. (2008, Obstet Gynecol), Topical gabapentin for vulvodynia Retrospective case series of topical 2, 6% gabapentin compounded preparations in women with localized and generalized vulvodynia 51 Median 8 weeks Symptomatic improvement in the majority of patients; provides the largest case-series support for topical compounded gabapentin in vulvodynia 27
Knezevic et al. (2017, Pain Management), Compounded topical analgesics review Narrative review of single-agent and compounded topical analgesics including gabapentin, ketamine, amitriptyline, lidocaine, and baclofen for chronic neuropathic pain — — Consolidates case-series evidence for topical compounded gabapentin alone and in combination preparations; identifies localized peripheral neuropathic pain as the principal indication and notes the limited evidence base 28
Dunlop (2016, Addiction), Smith commentary Editorial commentary on the Smith 2016 systematic review of gabapentin misuse — — Emphasizes the clinical implications of the misuse signal for prescribers and pharmacists and recommends screening before prescribing in populations with substance use history 22

Mechanism detail

Detailed Mechanism of Compounded Gabapentin

α2δ-1 is one of four α2δ subunit isoforms (α2δ-1 through α2δ-4) that associate with the pore-forming α1 subunit of voltage-gated calcium channels. The α2δ-1 subunit is upregulated in dorsal root ganglion neurons and dorsal horn after peripheral nerve injury and in seizure foci, providing a mechanistic substrate for gabapentin's selectivity in pathologic states. The radioligand binding studies by Gee et al. (1996) demonstrated saturable, high-affinity gabapentin binding to a porcine brain membrane fraction that was subsequently identified as the α2δ-1 subunit 1, and subsequent work mapped the binding site to a specific RRR/RKR motif in the von Willebrand factor type A domain of α2δ-1 31.

Downstream, reduced calcium influx at the presynaptic terminal decreases neurotransmitter vesicle fusion in a use-dependent manner. The mechanism predicts a state-dependent profile, therapeutic in sensitized or pathologically active circuits, comparatively quiet in normal physiology, that matches gabapentin's clinical safety profile of low intrinsic neurologic toxicity outside the dose-dependent sedation common to centrally active medications 31. The mechanism review by Sills (2006) synthesized the α2δ literature and remains the standard mechanistic reference 2.

Pharmacokinetically, oral gabapentin absorption is mediated by the saturable L-type amino acid transporter in the proximal small intestine. Bioavailability decreases with increasing dose (60% at 300 mg, ~35% at 1600 mg per dose), a non-linearity that motivates divided dosing (typically three times daily for immediate-release Neurontin). Gabapentin is not metabolized, is not bound to plasma proteins, and is eliminated unchanged in the urine with a half-life of 5, 7 hours and clearance proportional to creatinine clearance. Dose adjustment is required for renal impairment per the Neurontin and Gralise labels 2930. Gabapentin enacarbil (Horizant) is an actively transported prodrug absorbed across the entire small intestine and colon via MCT-1 and SMVT transporters; it is enzymatically cleaved to gabapentin during absorption, producing extended-release gabapentin exposure with linear, dose-proportional pharmacokinetics that overcome the saturable absorption of the parent drug 151617 31.

Pharmacology

Compounded Gabapentin Pharmacokinetics & Pharmacodynamics

Pharmacokinetics

Immediate-release gabapentin (Neurontin) is absorbed by the saturable L-type amino acid transporter in the proximal small intestine, producing dose-dependent bioavailability that decreases from approximately 60% at 300 mg per dose to ~35% at 1600 mg per dose. Tmax is approximately 2, 3 hours after oral dosing; the drug is not bound to plasma proteins (<3%), is not metabolized, and is eliminated unchanged in the urine with clearance proportional to creatinine clearance and a half-life of 5, 7 hours 29 17.

Gralise (gastric-retentive once-daily) achieves comparable steady-state AUC to divided-dose immediate-release gabapentin at 1800 mg/day with a different concentration-time profile that supports once-daily evening dosing 30. Gabapentin enacarbil (Horizant) is an actively transported prodrug absorbed across the entire small intestine and colon via MCT-1 and SMVT transporters; it is rapidly cleaved by non-specific carboxylesterases during absorption to gabapentin, producing dose-proportional gabapentin exposure that overcomes the saturable absorption of the parent drug 311516.

Compounded oral preparations should be assumed to follow the saturable absorption profile of immediate-release gabapentin and to require equivalent renal-impairment dose adjustment 17. Topical 6, 10% compounded gabapentin has not been characterized in formal pharmacokinetic studies; systemic absorption from a small area of intact skin is typically negligible but cannot be assumed in damaged or inflamed skin, in occluded preparations, or at extremes of body-surface coverage.

Pharmacodynamics

Pharmacodynamic effects are mediated by high-affinity binding to the α2δ-1 auxiliary subunit of voltage-gated calcium channels in the central nervous system, with downstream reduction of presynaptic calcium influx and excitatory neurotransmitter release in sensitized nociceptive and epileptogenic circuits 12. Clinically measured endpoints include pain score reduction (postherpetic neuralgia, painful diabetic peripheral neuropathy, fibromyalgia, hot flashes), seizure frequency (partial-onset epilepsy), RLS symptom severity (gabapentin enacarbil for primary RLS), and drinking outcomes (alcohol use disorder) 29.

Effects on sedation, dizziness, and ataxia are the principal dose-limiting pharmacodynamic effects and are typically concentrated in the titration period 29. Tolerance to these effects develops in most patients over 1, 2 weeks at steady dose.

Comparative formulations

Comparing Compounded Gabapentin Formulations

Three manufactured products are not interchangeable. Neurontin (immediate-release) requires three-times-daily dosing because of saturable absorption that limits per-dose bioavailability above approximately 600, 900 mg. Gralise (gastric-retentive) achieves comparable steady-state exposure to Neurontin at 1800 mg/day with once-daily evening dosing and a different concentration-time profile. Horizant (gabapentin enacarbil prodrug) is absorbed across the entire small intestine and colon, producing dose-proportional gabapentin exposure that supports 600 mg once daily for RLS or twice daily for PHN 303115.

Compounded oral preparations follow the immediate-release pharmacokinetic profile and are not bioequivalent to Gralise or Horizant. Clinicians should not substitute a compounded oral preparation for Gralise or Horizant without explicit re-titration. Topical 6, 10% compounded gabapentin is a distinct route with no commercial reference product and should be prescribed as a separate clinical entity rather than as a substitute for oral therapy 291617.

Storage

Compounded Gabapentin Storage and Handling

Manufactured Neurontin capsules and tablets are stored at controlled room temperature (20, 25°C). Neurontin oral solution is stored refrigerated at 2, 8°C 29. Gralise and Horizant tablets are stored at controlled room temperature 3031. Compounded oral suspensions, capsules, and topical preparations are stored per the pharmacy's stability data and assigned beyond-use date under USP <795> for nonsterile preparations 35. Beyond-use dates for compounded gabapentin oral suspensions are typically 14, 90 days refrigerated depending on vehicle, preservative system, and supporting stability data.

Compounded preparations should be dispensed in the original pharmacy-labeled container with clear storage instructions; patients should be educated on refrigeration requirements for oral suspensions and on disposal of expired preparations.

RonanRx operations

Compounded Gabapentin Compounding & Operations

503A compounding

Compounded gabapentin is prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies. RonanRx prepares nonsterile oral suspensions, capsules, and topical preparations per USP General Chapter <795> with documented active ingredient sourcing, gravimetric verification, beyond-use date assignment from supporting stability data, and lot traceability from API source through dispensing 35.

For oral preparations that are essentially copies of commercially available Neurontin (immediate-release capsule, tablet, or 250 mg/5 mL solution), the FDA section 503A essentially-a-copy guidance restricts compounding to documented patient-specific clinical needs the manufactured product cannot meet 33 34. Topical 6, 10% compounded gabapentin for localized neuropathic pain is a distinct route not commercially manufactured and is therefore not subject to the essentially-a-copy restriction. Custom-strength capsules to support an individualized titration step are evaluated case-by-case against the essentially-a-copy threshold.

Each batch is documented per state board of pharmacy retention rules with full traceability from API lot through dispensing, including ingredient identity verification, master formulation record, batch compounding record, and beyond-use date assignment basis 34.

Pharmacist review

Each prescription for compounded gabapentin undergoes pharmacist review prior to dispensing. The review confirms: a documented patient-specific clinical reason that the manufactured Neurontin, Gralise, or Horizant product is not appropriate (excipient sensitivity, dysphagia at a custom strength, individualized titration step, or topical localized use); appropriate renal-impairment dose adjustment per manufactured-product labels 29; concomitant medication review with particular attention to opioids, benzodiazepines, and other CNS depressants given the FDA 2019 respiratory-depression safety communication 32 and population-scale mortality evidence with opioids 23; and screening for history of substance use disorder given the documented misuse signal 212526 3031.

RonanRx does not fill prescriptions that read as routine substitution of compounded for manufactured product without documented clinical rationale, consistent with FDA guidance on compounded copies of commercially available drugs 33 30. Pharmacist clinical judgment is the principal mitigation against compounding-specific risks including dose-strength errors and excipient variability.

Quality and traceability

Active pharmaceutical ingredients are sourced from FDA-registered facilities with documented certificates of analysis. Each compounded batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, supporting stability basis, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements with master formulation records and batch compounding records available for inspection.

Cold chain

Compounded gabapentin oral suspensions are typically refrigerated products with beyond-use dates of 14, 90 days depending on vehicle, preservative system, and supporting stability data. Refrigerated transport is used between the compounding pharmacy and the patient when required by the BUD assignment, with temperature monitoring through the shipment as applicable. Compounded capsules and topical preparations are typically stored at controlled room temperature and do not require cold-chain transport 35. Manufactured Neurontin oral solution is the relevant cold-chain reference product 29.

FAQ

Frequently Asked Questions About Compounded Gabapentin

Is compounded gabapentin the same as Neurontin, Gralise, or Horizant?

No. Neurontin, Gralise, and Horizant are FDA-approved manufactured gabapentin products 293031. Compounded gabapentin is pharmacy-prepared on a patient-specific prescription and is not bioequivalent to the manufactured products. Compounded drugs are not FDA-approved 34.

When is compounded gabapentin appropriate?

Three typical scenarios: (1) a pediatric or dysphagia patient who needs an oral suspension at a custom strength, excipient profile, or volume that the commercial Neurontin 250 mg/5 mL solution cannot meet; (2) a documented sensitivity to a dye, sweetener, or excipient in the manufactured product that requires a custom capsule or suspension; and (3) topical 6, 10% gabapentin cream or gel for off-label localized peripheral neuropathic pain, a route that is not commercially manufactured 2728. Cost or preference does not qualify under FDA section 503A 33.

Does gabapentin work the same way as a GABA medication?

No. Despite the GABA structural similarity in its name, gabapentin does not bind GABA receptors. It binds the α2δ-1 auxiliary subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and excitatory neurotransmitter release in sensitized nerve pathways 1. The α2δ-1 mechanism is shared with pregabalin (Lyrica) 2.

What is gabapentin FDA-approved for?

Three approved indications across three products: (1) adjunctive therapy for partial-onset seizures in adults and pediatric patients ≥3 years (Neurontin); (2) postherpetic neuralgia in adults (Neurontin, Gralise, Horizant); and (3) moderate-to-severe primary restless legs syndrome in adults (Horizant only, the gabapentin enacarbil prodrug) 293031. Many other uses (diabetic neuropathy, fibromyalgia, hot flashes, alcohol use disorder, anxiety) are off-label but supported by randomized evidence.

How well does gabapentin work for nerve pain?

The Cochrane 2017 systematic review of 37 studies (>5,900 participants) reports that gabapentin 1800, 3600 mg/day produces 50% or greater pain reduction in approximately 30, 40% of patients with postherpetic neuralgia or painful diabetic peripheral neuropathy versus 10, 20% with placebo, a number-needed-to-treat of approximately 6, 8 for substantial benefit. Evidence is weaker in other neuropathic pain conditions and absent in low back pain and sciatica 81920.

Can gabapentin cause breathing problems?

Yes, particularly when combined with opioids, benzodiazepines, or alcohol, in older adults, and in patients with chronic obstructive pulmonary disease or other respiratory impairment. FDA's December 2019 Drug Safety Communication required new warnings on gabapentinoid labels for this risk. Ontario population data show a 49% increase in the odds of opioid-related death with concomitant gabapentin and opioids vs opioids alone 3223.

Is gabapentin addictive?

Gabapentin is not federally scheduled as a controlled substance in the United States but is a scheduled drug in several states. Misuse and diversion are documented at population scale, particularly among patients with opioid use disorder, who may use gabapentin to potentiate the effects of opioids 2125. Pharmacist screening at dispensing is the principal mitigation 26.

Does RonanRx sell compounded gabapentin directly to patients?

No. Compounded gabapentin requires a patient-specific prescription written by a licensed doctor for an identified patient with a documented clinical reason that the manufactured Neurontin, Gralise, or Horizant product is not appropriate, plus pharmacist review before dispensing 33. RonanRx is not a direct-to-consumer storefront 34.

Clinician resource

Download the Compounded Gabapentin Clinical Monograph (PDF)

The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.

Download information packet ↓

References

References

  1. [gee1996] Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. Journal of Biological Chemistry. 1996. PMID 8621444. (accessed 2026-05-11)
  2. [sills2006] Sills GJ. The mechanisms of action of gabapentin and pregabalin. Current Opinion in Pharmacology. 2006. PMID 16376147. (accessed 2026-05-11)
  3. [rowbotham1998] Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998. PMID 9846778. (accessed 2026-05-11)
  4. [backonja1998] Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998. PMID 9846777. (accessed 2026-05-11)
  5. [rice2001] Rice ASC, Maton S; Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001. PMID 11690735. (accessed 2026-05-11)
  6. [chadwick1998] Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, Pierce MW. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology. 1998. PMID 9818846. (accessed 2026-05-11)
  7. [marson2007] Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al.. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007. PMID 17382827. (accessed 2026-05-11)
  8. [wiffen2017] Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2017. PMID 28597471. (accessed 2026-05-11)
  9. [arnold2007] Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, Welge JA, Bishop F. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis and Rheumatism. 2007. PMID 17393438. (accessed 2026-05-11)
  10. [pandya2005] Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005. PMID 16139656. (accessed 2026-05-11)
  11. [mason2014] Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Internal Medicine. 2014. PMID 24190578. (accessed 2026-05-11)
  12. [pande1999_socphobia] Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology. 1999. PMID 10440462. (accessed 2026-05-11)
  13. [pande2000_panic] Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR. Placebo-controlled study of gabapentin treatment of panic disorder. Journal of Clinical Psychopharmacology. 2000. PMID 10917408. (accessed 2026-05-11)
  14. [hayes2012] Hayes WJ, Lemon MD, Farver DK. Gabapentin enacarbil for treatment of restless legs syndrome in adults. Annals of Pharmacotherapy. 2012. PMID 22298601. (accessed 2026-05-11)
  15. [lal2011] Lal R, Sukbuntherng J, Ho J, Cundy KC. A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. International Journal of Clinical Pharmacology and Therapeutics. 2011. PMID 21255527. (accessed 2026-05-11)
  16. [lal2013] Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. Journal of Clinical Pharmacology. 2013. PMID 23400741. (accessed 2026-05-11)
  17. [cundy2010] Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. International Journal of Clinical Pharmacology and Therapeutics. 2010. PMID 20137764. (accessed 2026-05-11)
  18. [tiippana2007] Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesthesia and Analgesia. 2007. PMID 17513656. (accessed 2026-05-11)
  19. [enke2018] Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, Maher CG, Lin CC. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. Canadian Medical Association Journal. 2018. PMID 29970367. (accessed 2026-05-11)
  20. [mathieson2017] Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, Day RO, Billot L, Pik J, Jan S, Lin CC. Trial of Pregabalin for Acute and Chronic Sciatica. New England Journal of Medicine. 2017. PMID 28328324. (accessed 2026-05-11)
  21. [smith2016] Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016. PMID 27265421. (accessed 2026-05-11)
  22. [dunlop2016] Dunlop AJ. Commentary on Smith et al. (2016): Gabapentin-looks like a drug that can be misused…, probably is a drug that can be misused. Addiction. 2016. PMID 27273386. (accessed 2026-05-11)
  23. [gomes2017] Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Medicine. 2017. PMID 28972983. (accessed 2026-05-11)
  24. [goodman2019] Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Internal Medicine. 2019. PMID 30907944. (accessed 2026-05-11)
  25. [evoy2021] Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ. Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. Journal of Clinical Pharmacology. 2021. PMID 34396549. (accessed 2026-05-11)
  26. [covvey2023] Covvey JR, Blakely ML, Singh R, Peckham AM, Evoy KE. Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. Research in Social and Administrative Pharmacy. 2023. PMID 36503683. (accessed 2026-05-11)
  27. [boardman2008] Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. Obstetrics and Gynecology. 2008. PMID 18757655. (accessed 2026-05-11)
  28. [knezevic2017] Knezevic NN, Tverdohleb T, Nikibin F, Knezevic I, Candido KD. Management of chronic neuropathic pain with single and compounded topical analgesics. Pain Management. 2017. PMID 29125423. (accessed 2026-05-11)
  29. [fda_label_neurontin] U.S. Food and Drug Administration. Neurontin (gabapentin) capsules, tablets, oral solution — FDA Prescribing Information. FDA Drug Approval Package. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf (accessed 2026-05-11)
  30. [fda_label_gralise] U.S. Food and Drug Administration. Gralise (gabapentin) tablets — FDA Prescribing Information. FDA Drug Approval Package. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022544s031lbl.pdf (accessed 2026-05-11)
  31. [fda_label_horizant] U.S. Food and Drug Administration. Horizant (gabapentin enacarbil) extended-release tablets — FDA Prescribing Information. FDA Drug Approval Package. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022399s014lbl.pdf (accessed 2026-05-11)
  32. [fda_safety_2019] U.S. Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). FDA Drug Safety Communication. 2019. https://wayback.archive-it.org/7993/20201221225906/https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin (accessed 2026-05-11)
  33. [fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
  34. [fda503a] U.S. Food and Drug Administration. Compounding Laws and Policies — Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Drug Compounding. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies (accessed 2026-05-11)
  35. [usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)

How to access

How to Access Compounded Gabapentin

Compounded Compounded Gabapentin is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.

For doctors

Offer this medication.

A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.

Offer this medication →

Patient with a doctor

Receive your prescription.

If your doctor has already prescribed Compounded Gabapentin, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.

Sign up →

Patient without a doctor

Find a partner clinic.

RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Compounded Gabapentin.

Find a partner clinic →

Related